Komori
Dividends4559ZERIA PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Notice Concerning Revision of Year-End Dividend Forecast (Increase)

The year-end dividend forecast for the fiscal year ending March 2027 was increased by ¥1, from ¥25 to ¥26 per share. Accordingly, the annual dividend forecast was also increased from ¥50 to ¥51.

Worth reading
61In focus
Scored from 4 of 5 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
1
Yen per share
Wording
Definitive
How definitive the wording is.

Dividend per share

Fiscal year ending March 2027
51YenRevised annual dividend per sharePrevious forecast ¥50, change ¥+1(+2.0%)
Previous-period resultsPrevious forecastAfter revision

Each vertical step represents one dividend payment, and the total height of the accumulated steps represents the annual dividend for the period. For periods showing only the annual amount, the payment breakdown is not provided, so only the end point is plotted.

Dividend per shareyen¥25→¥26+4.0%
Whether Submission to the General Meeting of Shareholders Is RequiredBoard of directors resolution only
Dividend policy

The Company positions the return of profits to shareholders as one of its most important management priorities and adopts as its basic dividend policy the payment of stable and continuous dividends.

Dividend per share
ItemDetails
Dividend per share25 yen → 26 yen(+4.0%)
Total Annual Dividends50 yen → 51 yen(+2.0%)
Previous-period results (per share)Interim 24 yen / End of period 25 yen / Annual 49 yen
Dividend policyThe Company positions the return of profits to shareholders as one of its most important management priorities and adopts as its basic dividend policy the payment of stable and continuous dividends.
Whether Submission to the General Meeting of Shareholders Is RequiredBoard of directors resolution only
Fiscal Period CoveredFiscal year ending March 2027
Items this document does not state (6)
Total dividendsRecord dateEffective dateSource of dividendsBreakdown of Regular, Commemorative and Special DividendsPayout ratio

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Because performance through the second quarter and other factors were taken into consideration. The Company also positions the return of profits to shareholders as one of its most important management priorities and states its basic policy of paying stable and continuous dividends.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Concerning Revision of Year-End Dividend Forecast (Increase) | ZERIA PHARMACEUTICAL CO.,LTD. (4559) timely disclosure | Komori